이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xspray Pharma 관리

관리 기준 확인 2/4

Xspray Pharma's CEO는 Per Andersson, Jan2006 에 임명되었습니다 의 임기는 18.42 년입니다. 총 연간 보상은 SEK 3.74M, 70.5% 로 구성됩니다. 70.5% 급여 및 29.5% 보너스(회사 주식 및 옵션 포함). 는 SEK 15.52M 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 15.52M. 경영진과 이사회의 평균 재임 기간은 각각 0.6 년과 5.1 년입니다.

주요 정보

Per Andersson

최고 경영자

SEK 3.7m

총 보상

CEO 급여 비율	70.5%
CEO 임기	18.5yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Per Andersson 의 보수는 Xspray Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 4m	SEK 3m	-SEK 180m
Sep 30 2023	n/a	n/a	-SEK 180m
Jun 30 2023	n/a	n/a	-SEK 170m
Mar 31 2023	n/a	n/a	-SEK 148m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 132m
Sep 30 2022	n/a	n/a	-SEK 128m
Jun 30 2022	n/a	n/a	-SEK 114m
Mar 31 2022	n/a	n/a	-SEK 102m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 97m
Sep 30 2021	n/a	n/a	-SEK 60m
Jun 30 2021	n/a	n/a	-SEK 57m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 52m
Sep 30 2020	n/a	n/a	-SEK 56m
Jun 30 2020	n/a	n/a	-SEK 55m
Mar 31 2020	n/a	n/a	-SEK 49m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 41m
Jun 30 2019	n/a	n/a	-SEK 34m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 17m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 14m

보상 대 시장: Per 의 총 보상 ($USD 358.65K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 479.09K ).

보상과 수익: 회사가 수익성이 없는 동안 Per 의 보상이 증가했습니다.

CEO

Per Andersson (57 yo)

18.5yrs

테뉴어

SEK 3,743,000

보상

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

리더십 팀

이름	위치	테뉴어	보상	소유권
Per Andersson	Chief Executive Officer	18.5yrs	SEK 3.74m	0.57% SEK 9.9m
Mustafa Demirbüker	Co-Founder and Science Director	no data	데이터 없음	데이터 없음
Niklas Adenborg	Chief Financial Officer	no data	데이터 없음	데이터 없음
Linda Glimberg	Chief Operating Officer	less than a year	데이터 없음	0.0053% SEK 91.4k
Kerstin Hasselgren	Senior Advisor & Head of IR	less than a year	데이터 없음	0.024% SEK 419.0k
Charlotta Liljebris	Senior Vice President of Research & Development	6.5yrs	데이터 없음	0.0089% SEK 152.5k
Edward Jordan	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Anette Abrahamsson	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	0.0044% SEK 76.2k
Christer Hallgren	Senior Vice President of Intellectual Property	6.5yrs	데이터 없음	0.089% SEK 1.5m

0.7yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: XSPRAY 의 관리팀은 경험 (평균 재직 기간 0.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Maris Hartmanis	Independent Director	9.5yrs	SEK 323.00k	0.092% SEK 1.6m
Carl-Johan Spak	Independent Director	9.5yrs	SEK 270.00k	데이터 없음
Anders Ekblom	Chairman	3.2yrs	SEK 510.00k	1.71% SEK 29.3m
Torbjörn Koivisto	Independent Director	7.5yrs	SEK 253.00k	0% SEK 0
Christine Lind	Independent Director	5.2yrs	SEK 270.00k	0% SEK 0
Anders Bladh	Director	3.2yrs	SEK 253.00k	2.18% SEK 37.4m
Robert Molander	Independent Director	2.2yrs	SEK 218.00k	0.030% SEK 508.0k

5.2yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: XSPRAY 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Xspray Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Recent updates

Director recently bought kr4.8m worth of stock

Price target decreased by 24% to kr91.50

New major risk - Share price stability

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Director recently bought kr143k worth of stock

Now 32% undervalued

Now 23% undervalued

Price target decreased by 11% to kr107

New minor risk - Share price stability

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Director recently bought kr504k worth of stock

Chief Executive Officer recently sold kr75k worth of stock

Chairman exercised options to buy kr24m worth of stock.

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

New minor risk - Share price stability

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

New major risk - Revenue and earnings growth

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR

Director recently bought kr2.1m worth of stock

Independent Director exercised options to buy kr97k worth of stock.

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Price target decreased by 21% to kr106

Chief Executive Officer recently sold kr2.2m worth of stock

Director recently bought kr135k worth of stock

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Price target decreased to kr116

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Price target decreased to kr116

No longer forecast to breakeven

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Independent Chairman of the Board Michael Jensen has left the company

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

New 90-day low: kr113

Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

New 90-day low: kr114

Chief Executive Officer exercised options and sold kr3.6m worth of stock

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

New 90-day low: kr127

Xspray Pharma Announces Results from Additional Bioequivalence Study

Xspray Pharma’S Hynap-Nilo Receives Fda Orphan Drug Designation for the Treatment of Chronic Myeloid Leukemia

New 90-day high: kr196

Xspray Pharma AB (publ) Decides to Await the Result of Two Ongoing Clinical Studies Before Submitting Its Anda Application

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Xspray Pharma AB (publ) to Report Q1, 2021 Results on May 06, 2021